Summer is definitely ahead of us, and this is a perfect time to be reminding your patients of all of the great options that you can offer them for ultraviolet protection and visual comfort—including contact lenses. This is particularly true for younger patients whom we often forget and are the most vulnerable to ocular damage from the sun.
Jason J. Nichols, OD, MPH, PhD
ABB OPTICAL GROUP Announces Sixth Annual ABB Cares Program
Starting Aug. 1, ABB Optical Group will be accepting applications for the Sixth Annual ABB Cares, its community grants program. This year, ABB Optical Group will award one ABB Cares Platinum Grant of $5,000, two Gold Grants of $2,500 each, and four Silver Grants of $1,000 to charities nominated by professionals in the eyecare industry, including optometrists, opticians, and office staff. Organizations do not need to focus on eye health to qualify for a grant. For more information or to submit an application, visit ABBOptical.com/ABBCares.
Johnson & Johnson Launches Acuvue Oasys with Transitions in the United Kingdom
Johnson & Johnson has announced that its Acuvue Oasys with Light Intelligent Technology contact lenses are available now in the United Kingdom. According to the company, the photochromic contact lenses will adapt to changing light conditions both indoors and outdoors, help eyes recover from bright light up to five seconds faster than normal, and reduce halos and starbursts around bright lights at night.
TheraTears SteriLid Antimicrobial Eyelid Cleanser and Facial Wash Available
Akorn Consumer Health released TheraTears SteriLid Antimicrobial 0.01% Hypochlorous Acid 2 ounce formula, which kills 99.9% of bacteria within 30 seconds and is pH balanced to be gentle on the eyelids, according to the company. TheraTears SteriLid Antimicrobial is cleared by the U.S. Food and Drug Administration as a medical device. It is an over-the-counter solution that is available in retail stores such as Rite Aid, CVS, and Walgreens as well as being available through Amazon and eyecare professional offices in the United States.
AAOF Announces the 2019 Award of Excellence in Contact Lens Patient Care Recipients
The American Academy of Optometry Foundation (AAOF) announced the 2019 Johnson & Johnson Vision Award of Excellence in Contact Lens Patient Care recipients. This award recognizes outstanding fourth-year student clinicians who have demonstrated skillful knowledge of the contact lens field. Each winner will receive a $500 educational award and a personalized plaque commemorating their accomplishment.
This year’s recipients and institutions attended include Mariana Ferraz, Illinois College of Optometry; Mackenzie Speers, Indiana University, School of Optometry; Kevin Hoang, Inter American University of Puerto Rico, School of Optometry; Stephanie Gee, Massachusetts College of Pharmacy and Health Sciences, School of Optometry; Kristina Aikens, Michigan College of Optometry at Ferris State University; Christina Wenn, Midwestern University Arizona, College of Optometry; Kendra Phillis, New England College of Optometry; Kelsey Buford, Northeastern State University Oklahoma College of Optometry; Karla Delgado, Nova Southeastern University, College of Optometry; Ryan Rutschilling, The Ohio State University, College of Optometry; Mari J. Fujimoto, Pacific University, College of Optometry; Nathan Housley, Pennsylvania College of Optometry at Salus University; Brandin Gwinner, Southern California College of Optometry at Marshall B. Ketchum University; Abagail Kirk, Southern College of Optometry; Nicole Poon, State University of New York, College of Optometry; Courtney Sartin, University of Alabama at Birmingham, School of Optometry; Valerie A. Lim, University of California Berkeley, School of Optometry; Theresa Hoang, University of Houston, College of Optometry; Jacquelyn M. Tyra, University of Missouri St. Louis, College of Optometry; Mikhail Lifshits, University of Montreal, School of Optometry; Christina Sally Abuata, University of the Incarnate Word, Rosenberg School of Optometry; Kirsten Carter, University of Waterloo, School of Optometry and Vision Science; and Kimber M. Kenzli, Western University of Health Sciences, College of Optometry.
Maria Giulia Muzzi, Italy
This image shows the advance of uveitis. On the right part of the sclera and cornea, we can notice some blue points. In addition, the pupil is deformed, and the superior part of the cornea doesn’t exist. We also noticed expansion of the blood vessels, particularly on the right-hand side of the photo.
We thank Maria Giulia Muzzi for this image and welcome photo submissions from our other readers! It is easy to submit a photo for consideration for publishing in Contact Lenses Today.. Simply visit http://www.cltoday.com/upload/upload.aspx to upload your image. Please include a detailed explanation of the photo and your full name, degree or title, and city/state/country.
SPECIALTY LENS SPACE
Karen DeLoss, OD
A Scleral Lens’ Kryptonite
Are scleral lenses your super power? In many cases, yes. But, what happens when they fail? Why wouldn’t a scleral lens work? With the popularity of sclerals, prescribing trends have skyrocketed over the past few years. However, there are still barriers to treatment, which is why scleral lenses may fail.
First, while the initial fitting cost is one barrier to treatment, it’s also important to keep in mind that future costs (such as the monthly costs of care and application solutions or costs of replacements) may be prohibitive. Second, literal barriers may exist. For example, either initially or during the natural course of the disease, symblepharons may preclude fitting due to limiting a comfortable fit, or they may progress to a point that alters a fit and/or limits a successful refit. Third, another concern is endothelial cell count. While no set lower limits of an appropriate cell count have been established, sclerals can result in slowly decreasing oxygen transmission and lead to eventual graft failure. For keratoconus patients, even a scleral lens may not meet patient’s expectations. Finally, there is a small subgroup of patients who may not tolerate lenses due to ocular pain. Concurrent treatments may be beneficial. However, in some cases, ocular pain may result in patient discomfort.
In any case, it is important to remember that there is no one panacea.
MATERIALS & DESIGNS
David L. Kading, OD
On Personal Reflections
Having the opportunity to write for a column like this one in Contact Lenses Today is a huge honor. We have readers from all over the world who tune in weekly to read what we have to say. It is super important to try to bring value to the audience to respect the time that people take to read our columns each week.
So, I decided to take a moment to stop and reflect. This year marks my 15th year as an optometrist. I was 24 when I graduated from optometry school. So, in many ways, I grew up in life as I grew into the role of a practitioner. I have noted that several key themes either have or are dominating my contact lens practice:
1. Daily disposable lenses are the best option for patients.
2. Myopia is a disease that must be slowed or halted.
3. Wearing contact lenses after the age of 40 is possible, and my job is to make it a reality.
4. Custom lens wearers deserve the best vision, health, and comfort, and it’s my responsibility to stay focused for them.
With these four “truths” as my North star, I go to work daily seeing patients. If someone comes in with a lens other than a daily disposable lens, my obligation is to show him or her a better alternative. If a child is heading toward myopia or is already there, we initiate a myopia management protocol. If someone is wearing lenses contrary to his or her best health, we intervene to help him or her wear lenses beyond the age of 40, and we educate and manipulate vision for those who have presbyopia. If a patient comes in with anything that is not as good as it can be for his or her specialty lenses, we look at all of the options—scleral, soft, hybrid, and corneal—to master that patient’s vision.
What are your North stars? Are you driving toward them with a ferocious diligence? Are you focused on long-term or short-term gains? Come to a conclusion of what is important to you and your patients, and do not stray from what is best and right.
Efficacy and Safety of Interventions to Control Myopia Progression in Children: An Overview of Systematic Reviews and Meta-Analyses
Myopia is a common visual disorder with increasing prevalence. Halting progression of myopia is critical, as high myopia can be complicated by a number of vision-compromising conditions.
In this study, a literature search was conducted in the following databases: Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), and Centre for Reviews and Dissemination (CRD) Health Technology Assessment (HTA) database. Systematic reviews and meta-analyses investigating the efficacy and safety of multiple myopia interventions versus control conditions were considered. Methodological quality and quality of evidence of eligible studies were assessed using the ROBIS tool and GRADE rating. The degree of overlapping of index publications in the eligible reviews was calculated with the corrected covered area (CCA).
Forty-four unique primary studies contained in 18 eligible reviews and involving 6,400 children were included in the analysis. CCA was estimated as 6.2% and thus considered moderate. Results demonstrated the superior efficacy of atropine eyedrops; 1% atropine versus placebo (change in refraction: –0.78D, [–1.30D to –0.25D] in one year), 0.03% to 0.05% atropine versus control (change in refraction: –0.51D, [–0.60D to –0.41D] in one year), 0.01% atropine versus control (change in refraction: –0.50D, [–0.76D to –0.24D] in one year). Atropine was followed by orthokeratology (axial elongation: –0.19mm, [–0.21mm to –0.16mm] in one year) and novel multifocal soft contact lenses (change in refraction: –0.15D, [–0.27D to –0.03D] in one year). With regard to adverse events, 1.0% atropine induced blurred near vision (odds ratio [OR] 9.47, [1.17 to 76.78]) and hypersensitivity reactions (OR 8.91, [1.04 to 76.03]).
The researchers noted that existing evidence has failed to convince doctors to uniformly embrace treatments for myopia progression control, possibly due to existence of some heterogeneity, reporting of side effects, and lack of long-term follow up. Research geared toward efficient interventions is still necessary.
Prousali E, Haidich AB, Fontalis A, Ziakas N, Brazitikos P, Mataftsi A. Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses. BMC Ophthalmol. 2019 May 9;19:106.